Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Friede

Showing results (381-390 of 393) with videos related to

Pageof 40
Sort By:
Journal of Electrocardiology|September 19, 2019
Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope) projectMarkus Zabel, Simon Schlögl, Andrzej Lubinski, et al.
European Journal of Heart Failure|April 29, 2025
Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR-HF2-DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trialsStefan D Anker, Tim Friede, Javed Butler, et al.
JACC. Basic to Translational Science|March 25, 2025
Impact of MEK Inhibition on Childhood RASopathy-Associated Hypertrophic CardiomyopathyCordula M Wolf, Martin Zenker, Olga Boleti, et al.
Annals of Neurology|December 12, 2023
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGADAnkelien Duchow, Judith Bellmann-Strobl, Tim Friede, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 27, 2024
Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGADVivien Häußler, Corinna Trebst, Daniel Engels, et al.
JAMA|March 30, 2025
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical TrialStefan D Anker, Tim Friede, Javed Butler, et al.
European Journal of Heart Failure|July 31, 2025
Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomesMahir Karakas, Tim Friede, Javed Butler, et al.
Journal of the American College of Cardiology|September 1, 2024
Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2Piotr Ponikowski, Tim Friede, Ralph Stephan von Bardeleben, et al.
European Journal of Heart Failure|June 7, 2024
Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trialsStefan D Anker, Tim Friede, Ralph Stephan von Bardeleben, et al.
The New England Journal of Medicine|August 31, 2024
Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral RegurgitationStefan D Anker, Tim Friede, Ralph-Stephan von Bardeleben, et al.
Pageof 40

Showing results (381-390 of 393) with videos related to

Sort By:
Pageof 40
Journal of Electrocardiology|September 19, 2019
Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope) projectMarkus Zabel, Simon Schlögl, Andrzej Lubinski, et al.
European Journal of Heart Failure|April 29, 2025
Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR-HF2-DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trialsStefan D Anker, Tim Friede, Javed Butler, et al.
JACC. Basic to Translational Science|March 25, 2025
Impact of MEK Inhibition on Childhood RASopathy-Associated Hypertrophic CardiomyopathyCordula M Wolf, Martin Zenker, Olga Boleti, et al.
Annals of Neurology|December 12, 2023
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGADAnkelien Duchow, Judith Bellmann-Strobl, Tim Friede, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 27, 2024
Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGADVivien Häußler, Corinna Trebst, Daniel Engels, et al.
JAMA|March 30, 2025
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical TrialStefan D Anker, Tim Friede, Javed Butler, et al.
European Journal of Heart Failure|July 31, 2025
Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomesMahir Karakas, Tim Friede, Javed Butler, et al.
Journal of the American College of Cardiology|September 1, 2024
Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2Piotr Ponikowski, Tim Friede, Ralph Stephan von Bardeleben, et al.
European Journal of Heart Failure|June 7, 2024
Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trialsStefan D Anker, Tim Friede, Ralph Stephan von Bardeleben, et al.
The New England Journal of Medicine|August 31, 2024
Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral RegurgitationStefan D Anker, Tim Friede, Ralph-Stephan von Bardeleben, et al.
Pageof 40